Lymphoma

• Health & Medicine

Immune-stimulating injection turns tumours into ‘cancer vaccine factories’ in mice

Injecting immune cell stimulants directly into a tumour could help the immune system spot and attack cancer cells, according to new research in mice. Injecting immune cell stimulants directly into a tumour could help the immune system spot and attack cancer cells, according to new research in mice.

8 April 2019

• Health & Medicine

Targeted lymphoma drug gets green light for NHS in England

People with a certain type of lymphoma will now have access to a targeted cancer drug, called brentuximab vedotin, on the NHS in England. People with a certain type of lymphoma will now have access to a targeted cancer drug, called brentuximab vedotin, on the NHS in England.

22 March 2019

• Health & Medicine

CAR T cell immunotherapy for lymphoma rejected in Scotland

Patients living with an aggressive form of lymphoma in Scotland will not get access to a new immunotherapy treatment after it was rejected for use on the NHS. Patients living with an aggressive form of lymphoma in Scotland will not get access to a new immunotherapy treatment after it was rejected for use on the NHS.

13 March 2019

• Health & Medicine

Double NHS decision for CAR T cell immunotherapy in Scotland

Two cancer immunotherapies have been reviewed for NHS use in Scotland as a treatment for some patients with aggressive blood cancer. Two cancer immunotherapies have been reviewed for NHS use in Scotland as a treatment for some patients with aggressive blood cancer.

13 February 2019

• Health & Medicine

Targeted drug not approved for certain lymphoma patients on the NHS

People with a certain type of lymphoma will not be able to receive a targeted cancer drug on the NHS in England. People with a certain type of lymphoma will not be able to receive a targeted cancer drug on the NHS in England.

20 December 2018

• Health & Medicine

‘Cutting edge’ CAR T cell immunotherapy approved in England. But is the NHS ready?

With two complex CAR T immunotherapies now approved on the NHS in England, we look at how the health service has had to react to these exciting new treatments. With two complex CAR T immunotherapies now approved on the NHS in England, we look at how the health service has had to react to these exciting new treatments.

5 October 2018

• Health & Medicine

NHS England to fund engineered cell therapy for adults with aggressive lymphoma

A cancer immunotherapy will be offered on the NHS in England to some adults with aggressive non-Hodgkin lymphoma, NHS England announced today. A cancer immunotherapy will be offered on the NHS in England to some adults with aggressive non-Hodgkin lymphoma, NHS England announced today.

5 October 2018

• Health & Medicine

Engineered cell therapy given initial ‘no’ for aggressive adult lymphoma on NHS in England

A cancer immunotherapy has been provisionally rejected as a treatment for some adults with an aggressive type of non-Hodgkin lymphoma on the NHS in England. A cancer immunotherapy has been provisionally rejected as a treatment for some adults with an aggressive type of non-Hodgkin lymphoma on the NHS in England.

19 September 2018

• Health & Medicine

Engineered cell therapy given initial ‘no’ for NHS in England

A cancer immunotherapy has been provisionally rejected as a treatment for some types of aggressive non-Hodgkin lymphoma on the NHS in England. A cancer immunotherapy has been provisionally rejected as a treatment for some types of aggressive non-Hodgkin lymphoma on the NHS in England.

30 August 2018

• Health & Medicine

Immunotherapy drug made available for some NHS patients with Hodgkin lymphoma

The immunotherapy drug pembrolizumab (Keytruda) can now be used to treat some patients with Hodgkin lymphoma on the NHS in England. The immunotherapy drug pembrolizumab (Keytruda) can now be used to treat some patients with Hodgkin lymphoma on the NHS in England.

27 July 2018

• Health & Medicine

Immune cell therapy results are 'landmark moment' in lymphoma treatment

Four in 10 patients with aggressive lymphoma were cancer-free 15 months after treatment with engineered immune cells, according to new clinical trial results. Four in 10 patients with aggressive lymphoma were cancer-free 15 months after treatment with engineered immune cells, according to new clinical trial results.

12 December 2017

• Health & Medicine

Immune-boosting antibody combination could improve lymphoma survival

Combining two different immunotherapy treatments could dramatically improve lymphoma survival. Combining two different immunotherapy treatments could dramatically improve lymphoma survival.

30 November 2017